Zevra Therapeutics, Inc. has grown revenue 102% a year over three years and 37% a year over five. Revenue growth, 3-year annual rate: +102% (Biotechnology median +17%). Revenue growth, 5-year rate: +37%, growth has picked up over the last three years. Years of annual history on file: 13, FY2013 to FY2025, as filed.

ZVRAZevra Therapeutics, Inc.

Healthcare

$11.00+7.9% 1Y

$11.00

$8.1052 weeks$14.74

Is it growing?

Mixed

Neither accelerating nor breaking down: revenue growing +119% year on year and operating margin widening (+349.3 points), but earnings down −500% year on year.

2 good, 1 to watch

Revenue trend+119% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +37% a year.

Earnings trend−500% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

Margin direction+349.3 points operating

Trailing-twelve-month operating margin, 57.4% now against -291.9% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is ZVRA growing?

Zevra Therapeutics, Inc. has grown revenue 102% a year over three years and 37% a year over five.

+102%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +37%
Revenue growth, 5-year rate · +102% over three · growth has picked up over the last three years
Years of annual history on file: 13
Years of annual history on file · FY2013 to FY2025, as filed

Details›